Co-Diagnostics, Inc. filed a Form 8-K on November 20, 2026, disclosing that the company borrowed $1.0 million from J.J. Astor & Co. on November 18, 2026, under a senior secured convertible installment promissory note with an original principal amount of $1.35 million.
Key Highlights
- Loan funded: J.J. Astor & Co. funded $1.0 million on November 18, 2026, under the existing Loan Agreement dated October 9, 2026.
- Original principal: The Additional Note carries an original principal amount of $1.35 million, reflecting a factor rate of 1.35 times the funded amount.
- Net proceeds: After a $40,000 origination fee retained by the lender, net cash proceeds to the company were $960,000 before other transaction expenses.
- Repayment schedule: The note requires 30 weekly installment payments of $45,000 beginning November 25, 2026, with a final maturity date of June 16, 2027.
- Conversion feature: The lender may convert payment amounts into common stock at the greater of 90% of the lowest volume-weighted average price over the preceding 10 trading days or the applicable Nasdaq minimum price floor.
- Reverse stock split deadline: The company is required to cause a previously approved reverse stock split to become effective on or before November 24, 2026; failure constitutes an event of default under the Additional Note.
Co-Diagnostics Issues $1.35M Convertible Note to J.J. Astor Under October Loan Agreement
According to the filing, Co-Diagnostics, Inc. (NASDAQ:CODX), a Utah-incorporated molecular diagnostics company headquartered at 2401 S. Foothill Drive, Suite D, Salt Lake City, Utah, drew the additional loan contemplated by its Loan Agreement with J.J. Astor & Co., originally dated October 9, 2026. The company disclosed that it intends to use the net proceeds of $960,000 for general working capital purposes. The note is secured by a senior-priority lien on substantially all assets of the company and its existing subsidiaries under a Pledge and Security Agreement and Subsidiary Guarantee, both dated October 9, 2026.
The filing states that the company may prepay the Additional Note at any time without penalty. If the note is paid in full within 45 days of its funding date and no event of default has occurred, the filing discloses that the repayment amount will be reduced to reflect a factor rate of 1.29 times the applicable funded amount, less all weekly installment payments previously made. Upon an event of default, the outstanding balance becomes immediately due, the outstanding principal of all notes under the Loan Agreement increases to 120% of then-outstanding amounts, and default interest accrues at 19% per annum, compounded daily, according to the filing.
The filing also disclosed that the company and the lender agreed to waive certain conditions under the Loan Agreement. These conditions would otherwise have required the additional loan to be requested and funded no earlier than December 8, 2026, and on at least five business days' notice. The parties additionally waived the condition that the company's common stock closing price on the trading day immediately preceding the funding date be at least $1.00 per share. The Additional Note was issued in reliance on the exemption from Securities Act registration provided by Section 4(a)(2) and/or Rule 506(b) of Regulation D, with the lender representing it is an "accredited investor" as defined in Rule 501(a) of Regulation D.
What Was Disclosed
Co-Diagnostics filed an 8-K reporting the November 18, 2026 funding of a $1.0 million additional loan from J.J. Astor & Co., resulting in a $1.35 million senior secured convertible installment promissory note with 30 weekly payments of $45,000 and a final maturity of June 16, 2027.



Please wait processing your request...